Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Puig

Showing results (1-10 of 423) with videos related to

Pageof 43
Sort By:
The British Journal of Dermatology|August 11, 2019
Significant weight loss improves and prevents psoriasis and psoriatic arthritis in obese patients: a Critically Appraised Topic and a call to actionL Puig
Actas Dermo-Sifiliograficas|June 10, 2019
Patient-Reported Outcomes in Psoriasis Validated in Spain: PROs and ConsL Puig
Business and Health|August 7, 1989
A new look at an old problem: long-term careL Puig
The British Journal of Dermatology|August 30, 2012
Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenariosL Puig
Actas Dermo-Sifiliograficas|February 26, 2013
Methotrexate: new therapeutic approachesL Puig
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2012
Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasisL Puig
The British Journal of Dermatology|December 13, 2019
Psoriasis Area and Severity Index vs. pharmacokinetics: can monitoring 4-week postinjection ustekinumab concentrations in patients with suboptimal response be clinically relevant?L Puig
Actas Dermo-Sifiliograficas|November 20, 2012
Cardiovascular risk and psoriasis: the role of biologic therapyL Puig
Actas Dermo-Sifiliograficas|January 22, 2014
Treatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs switch to another biologic after failure of maintenance therapyL Puig
Actas Dermo-Sifiliograficas|December 17, 2008
[Infliximab: patients selection]L Puig
Pageof 43

Showing results (1-10 of 423) with videos related to

Sort By:
Pageof 43
The British Journal of Dermatology|August 11, 2019
Significant weight loss improves and prevents psoriasis and psoriatic arthritis in obese patients: a Critically Appraised Topic and a call to actionL Puig
Actas Dermo-Sifiliograficas|June 10, 2019
Patient-Reported Outcomes in Psoriasis Validated in Spain: PROs and ConsL Puig
Business and Health|August 7, 1989
A new look at an old problem: long-term careL Puig
The British Journal of Dermatology|August 30, 2012
Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenariosL Puig
Actas Dermo-Sifiliograficas|February 26, 2013
Methotrexate: new therapeutic approachesL Puig
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2012
Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasisL Puig
The British Journal of Dermatology|December 13, 2019
Psoriasis Area and Severity Index vs. pharmacokinetics: can monitoring 4-week postinjection ustekinumab concentrations in patients with suboptimal response be clinically relevant?L Puig
Actas Dermo-Sifiliograficas|November 20, 2012
Cardiovascular risk and psoriasis: the role of biologic therapyL Puig
Actas Dermo-Sifiliograficas|January 22, 2014
Treatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs switch to another biologic after failure of maintenance therapyL Puig
Actas Dermo-Sifiliograficas|December 17, 2008
[Infliximab: patients selection]L Puig
Pageof 43